News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Drugs & Diseases

      dexchlorpheniramine (Rx)

      Brand and Other Names:
      • Print

      Dosing & Uses

      AdultPediatricGeriatric

      Dosage Forms & Strengths

      syrup

      • 2mg/5mL

      Allergy Symptoms

      2 mg PO q4-6hr

      Dosage Forms & Strengths

      syrup

      • 2mg/5mL

      Allergy Symptoms

      2-6 years: Syrup: 0.5 mg PO q4-6hr

      6-11 years: (syrup) 1 mg PO q4-6hr

      >12 years: As adults; (syrup) 2 mg PO q4-6hr

      Dose at lower end of dosage range (2 mg PO q4-6hr) or administer less frequently

      Nonanticholinergic antihistamines should be considered first when treating allergic reactions (Beers Criteria)

      Avoid use in elderly because of high incidence of anticholinergic effects

      Clearance reduced with advanced age, greater risk of confusion, dry mouth, constipation, and other anticholinergic effects and toxicity

      May exacerbate existing lower urinary conditions or benign prostatic hyperplasia

      Next:

      Interactions

      Interaction Checker

      and dexchlorpheniramine

      No Results

         activity indicator 
        No Interactions Found
        Interactions Found

        Contraindicated

          Serious - Use Alternative

            Significant - Monitor Closely

              Minor

                All Interactions Sort By:
                 activity indicator 

                Contraindicated (0)

                  Serious - Use Alternative (8)

                  • calcium/magnesium/potassium/sodium oxybates

                    dexchlorpheniramine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

                  • eluxadoline

                    dexchlorpheniramine, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions.

                  • metoclopramide intranasal

                    dexchlorpheniramine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

                  • olopatadine intranasal

                    dexchlorpheniramine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.

                  • pitolisant

                    dexchlorpheniramine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.

                  • ropeginterferon alfa 2b

                    ropeginterferon alfa 2b and dexchlorpheniramine both increase Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity.

                  • sodium oxybate

                    dexchlorpheniramine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

                  • tranylcypromine

                    tranylcypromine increases effects of dexchlorpheniramine by Other (see comment). Avoid or Use Alternate Drug. Comment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .

                  Monitor Closely (204)

                  • acrivastine

                    acrivastine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • albuterol

                    dexchlorpheniramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • alfentanil

                    dexchlorpheniramine and alfentanil both increase sedation. Use Caution/Monitor.

                  • alprazolam

                    dexchlorpheniramine and alprazolam both increase sedation. Use Caution/Monitor.

                  • amifampridine

                    dexchlorpheniramine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.

                  • amisulpride

                    amisulpride and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • amitriptyline

                    dexchlorpheniramine and amitriptyline both increase sedation. Use Caution/Monitor.

                  • amobarbital

                    dexchlorpheniramine and amobarbital both increase sedation. Use Caution/Monitor.

                  • amoxapine

                    dexchlorpheniramine and amoxapine both increase sedation. Use Caution/Monitor.

                  • apomorphine

                    dexchlorpheniramine and apomorphine both increase sedation. Use Caution/Monitor.

                  • arformoterol

                    dexchlorpheniramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • aripiprazole

                    dexchlorpheniramine and aripiprazole both increase sedation. Use Caution/Monitor.

                  • armodafinil

                    dexchlorpheniramine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • asenapine

                    asenapine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • asenapine transdermal

                    asenapine transdermal and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • avapritinib

                    avapritinib and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • azelastine

                    azelastine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • baclofen

                    dexchlorpheniramine and baclofen both increase sedation. Use Caution/Monitor.

                  • belladonna and opium

                    dexchlorpheniramine and belladonna and opium both increase sedation. Use Caution/Monitor.

                  • benperidol

                    dexchlorpheniramine and benperidol both increase sedation. Use Caution/Monitor.

                  • benzphetamine

                    dexchlorpheniramine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • brexanolone

                    brexanolone, dexchlorpheniramine. Either increases toxicity of the other by sedation. Use Caution/Monitor.

                  • brompheniramine

                    brompheniramine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • buprenorphine

                    dexchlorpheniramine and buprenorphine both increase sedation. Use Caution/Monitor.

                  • buprenorphine buccal

                    dexchlorpheniramine and buprenorphine buccal both increase sedation. Use Caution/Monitor.

                  • butabarbital

                    dexchlorpheniramine and butabarbital both increase sedation. Use Caution/Monitor.

                  • butalbital

                    dexchlorpheniramine and butalbital both increase sedation. Use Caution/Monitor.

                  • butorphanol

                    dexchlorpheniramine and butorphanol both increase sedation. Use Caution/Monitor.

                  • caffeine

                    dexchlorpheniramine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • carbinoxamine

                    carbinoxamine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • carisoprodol

                    dexchlorpheniramine and carisoprodol both increase sedation. Use Caution/Monitor.

                  • cenobamate

                    cenobamate, dexchlorpheniramine. Either increases effects of the other by sedation. Use Caution/Monitor.

                  • chloral hydrate

                    dexchlorpheniramine and chloral hydrate both increase sedation. Use Caution/Monitor.

                  • chlordiazepoxide

                    dexchlorpheniramine and chlordiazepoxide both increase sedation. Use Caution/Monitor.

                  • chlorpheniramine

                    chlorpheniramine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • chlorpromazine

                    dexchlorpheniramine and chlorpromazine both increase sedation. Use Caution/Monitor.

                  • chlorzoxazone

                    dexchlorpheniramine and chlorzoxazone both increase sedation. Use Caution/Monitor.

                  • cinnarizine

                    cinnarizine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • clemastine

                    clemastine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • clobazam

                    dexchlorpheniramine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

                  • clomipramine

                    dexchlorpheniramine and clomipramine both increase sedation. Use Caution/Monitor.

                  • clonazepam

                    dexchlorpheniramine and clonazepam both increase sedation. Use Caution/Monitor.

                  • clorazepate

                    dexchlorpheniramine and clorazepate both increase sedation. Use Caution/Monitor.

                  • clozapine

                    dexchlorpheniramine and clozapine both increase sedation. Use Caution/Monitor.

                  • codeine

                    dexchlorpheniramine and codeine both increase sedation. Use Caution/Monitor.

                  • cyclizine

                    cyclizine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • cyclobenzaprine

                    dexchlorpheniramine and cyclobenzaprine both increase sedation. Use Caution/Monitor.

                  • cyproheptadine

                    cyproheptadine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • dantrolene

                    dexchlorpheniramine and dantrolene both increase sedation. Use Caution/Monitor.

                  • daridorexant

                    dexchlorpheniramine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.

                  • desflurane

                    desflurane and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • desipramine

                    dexchlorpheniramine and desipramine both increase sedation. Use Caution/Monitor.

                  • deutetrabenazine

                    dexchlorpheniramine and deutetrabenazine both increase sedation. Use Caution/Monitor.

                  • dexfenfluramine

                    dexchlorpheniramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • dexmedetomidine

                    dexchlorpheniramine and dexmedetomidine both increase sedation. Use Caution/Monitor.

                  • dexmethylphenidate

                    dexchlorpheniramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • dextroamphetamine

                    dexchlorpheniramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • dextromoramide

                    dexchlorpheniramine and dextromoramide both increase sedation. Use Caution/Monitor.

                  • diamorphine

                    dexchlorpheniramine and diamorphine both increase sedation. Use Caution/Monitor.

                  • diazepam

                    dexchlorpheniramine and diazepam both increase sedation. Use Caution/Monitor.

                  • diazepam intranasal

                    diazepam intranasal, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.

                  • diethylpropion

                    dexchlorpheniramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • difelikefalin

                    difelikefalin and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • difenoxin hcl

                    dexchlorpheniramine and difenoxin hcl both increase sedation. Use Caution/Monitor.

                  • dimenhydrinate

                    dexchlorpheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.

                  • diphenhydramine

                    dexchlorpheniramine and diphenhydramine both increase sedation. Use Caution/Monitor.

                  • diphenoxylate hcl

                    dexchlorpheniramine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.

                  • dipipanone

                    dexchlorpheniramine and dipipanone both increase sedation. Use Caution/Monitor.

                  • dobutamine

                    dexchlorpheniramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • donepezil transdermal

                    donepezil transdermal, dexchlorpheniramine. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.

                  • dopamine

                    dexchlorpheniramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • dopexamine

                    dexchlorpheniramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • dosulepin

                    dexchlorpheniramine and dosulepin both increase sedation. Use Caution/Monitor.

                  • doxepin

                    dexchlorpheniramine and doxepin both increase sedation. Use Caution/Monitor.

                  • doxylamine

                    dexchlorpheniramine and doxylamine both increase sedation. Use Caution/Monitor.

                  • droperidol

                    dexchlorpheniramine and droperidol both increase sedation. Use Caution/Monitor.

                  • ephedrine

                    dexchlorpheniramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • epinephrine

                    dexchlorpheniramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • epinephrine racemic

                    dexchlorpheniramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • esketamine intranasal

                    esketamine intranasal, dexchlorpheniramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

                  • estazolam

                    dexchlorpheniramine and estazolam both increase sedation. Use Caution/Monitor.

                  • ethanol

                    dexchlorpheniramine and ethanol both increase sedation. Use Caution/Monitor.

                  • etomidate

                    etomidate and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • fenfluramine

                    dexchlorpheniramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • fentanyl

                    fentanyl, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

                  • fentanyl intranasal

                    fentanyl intranasal, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

                  • fentanyl transdermal

                    fentanyl transdermal, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

                  • fentanyl transmucosal

                    fentanyl transmucosal, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

                  • flibanserin

                    dexchlorpheniramine and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.

                  • fluphenazine

                    dexchlorpheniramine and fluphenazine both increase sedation. Use Caution/Monitor.

                  • flurazepam

                    dexchlorpheniramine and flurazepam both increase sedation. Use Caution/Monitor.

                  • formoterol

                    dexchlorpheniramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • gabapentin

                    gabapentin, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

                  • gabapentin enacarbil

                    gabapentin enacarbil, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

                  • ganaxolone

                    dexchlorpheniramine and ganaxolone both increase sedation. Use Caution/Monitor.

                  • glycopyrronium tosylate topical

                    glycopyrronium tosylate topical, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.

                  • gotu kola

                    gotu kola increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

                  • haloperidol

                    dexchlorpheniramine and haloperidol both increase sedation. Use Caution/Monitor.

                  • hawthorn

                    hawthorn increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

                  • hops

                    hops increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

                  • hyaluronidase

                    dexchlorpheniramine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. Comment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.

                  • hydromorphone

                    dexchlorpheniramine and hydromorphone both increase sedation. Use Caution/Monitor.

                  • hydroxyzine

                    dexchlorpheniramine and hydroxyzine both increase sedation. Use Caution/Monitor.

                  • iloperidone

                    dexchlorpheniramine and iloperidone both increase sedation. Use Caution/Monitor.

                  • imipramine

                    dexchlorpheniramine and imipramine both increase sedation. Use Caution/Monitor.

                  • isoproterenol

                    dexchlorpheniramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • kava

                    kava increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

                  • ketamine

                    ketamine and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • ketotifen, ophthalmic

                    dexchlorpheniramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

                  • lasmiditan

                    lasmiditan, dexchlorpheniramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

                  • lemborexant

                    lemborexant, dexchlorpheniramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

                  • levalbuterol

                    dexchlorpheniramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • levorphanol

                    dexchlorpheniramine and levorphanol both increase sedation. Use Caution/Monitor.

                  • lisdexamfetamine

                    dexchlorpheniramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • lofepramine

                    dexchlorpheniramine and lofepramine both increase sedation. Use Caution/Monitor.

                  • lofexidine

                    dexchlorpheniramine and lofexidine both increase sedation. Use Caution/Monitor.

                  • loprazolam

                    dexchlorpheniramine and loprazolam both increase sedation. Use Caution/Monitor.

                  • lorazepam

                    dexchlorpheniramine and lorazepam both increase sedation. Use Caution/Monitor.

                  • lormetazepam

                    dexchlorpheniramine and lormetazepam both increase sedation. Use Caution/Monitor.

                  • loxapine

                    dexchlorpheniramine and loxapine both increase sedation. Use Caution/Monitor.

                  • loxapine inhaled

                    dexchlorpheniramine and loxapine inhaled both increase sedation. Use Caution/Monitor.

                  • lurasidone

                    lurasidone, dexchlorpheniramine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.

                  • maprotiline

                    dexchlorpheniramine and maprotiline both increase sedation. Use Caution/Monitor.

                  • marijuana

                    dexchlorpheniramine and marijuana both increase sedation. Use Caution/Monitor.

                  • melatonin

                    dexchlorpheniramine and melatonin both increase sedation. Use Caution/Monitor.

                  • meperidine

                    dexchlorpheniramine and meperidine both increase sedation. Use Caution/Monitor.

                  • meprobamate

                    dexchlorpheniramine and meprobamate both increase sedation. Use Caution/Monitor.

                  • metaproterenol

                    dexchlorpheniramine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • metaxalone

                    dexchlorpheniramine and metaxalone both increase sedation. Use Caution/Monitor.

                  • methadone

                    dexchlorpheniramine and methadone both increase sedation. Use Caution/Monitor.

                  • methamphetamine

                    dexchlorpheniramine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • methocarbamol

                    dexchlorpheniramine and methocarbamol both increase sedation. Use Caution/Monitor.

                  • methylenedioxymethamphetamine

                    dexchlorpheniramine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • midazolam

                    dexchlorpheniramine and midazolam both increase sedation. Use Caution/Monitor.

                  • midazolam intranasal

                    midazolam intranasal, dexchlorpheniramine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

                  • midodrine

                    dexchlorpheniramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • mirtazapine

                    dexchlorpheniramine and mirtazapine both increase sedation. Use Caution/Monitor.

                  • modafinil

                    dexchlorpheniramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • morphine

                    dexchlorpheniramine and morphine both increase sedation. Use Caution/Monitor.

                  • motherwort

                    dexchlorpheniramine and motherwort both increase sedation. Use Caution/Monitor.

                  • moxonidine

                    dexchlorpheniramine and moxonidine both increase sedation. Use Caution/Monitor.

                  • nabilone

                    dexchlorpheniramine and nabilone both increase sedation. Use Caution/Monitor.

                  • nalbuphine

                    dexchlorpheniramine and nalbuphine both increase sedation. Use Caution/Monitor.

                  • norepinephrine

                    dexchlorpheniramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • nortriptyline

                    dexchlorpheniramine and nortriptyline both increase sedation. Use Caution/Monitor.

                  • olanzapine

                    dexchlorpheniramine and olanzapine both increase sedation. Use Caution/Monitor.

                  • opium tincture

                    dexchlorpheniramine and opium tincture both increase sedation. Use Caution/Monitor.

                  • orphenadrine

                    dexchlorpheniramine and orphenadrine both increase sedation. Use Caution/Monitor.

                  • oxazepam

                    dexchlorpheniramine and oxazepam both increase sedation. Use Caution/Monitor.

                  • oxycodone

                    dexchlorpheniramine and oxycodone both increase sedation. Use Caution/Monitor.

                  • oxymorphone

                    dexchlorpheniramine and oxymorphone both increase sedation. Use Caution/Monitor.

                  • paliperidone

                    dexchlorpheniramine and paliperidone both increase sedation. Use Caution/Monitor.

                  • papaveretum

                    dexchlorpheniramine and papaveretum both increase sedation. Use Caution/Monitor.

                  • papaverine

                    dexchlorpheniramine and papaverine both increase sedation. Use Caution/Monitor.

                  • passion flower

                    passion flower increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

                  • pentazocine

                    dexchlorpheniramine and pentazocine both increase sedation. Use Caution/Monitor.

                  • pentobarbital

                    dexchlorpheniramine and pentobarbital both increase sedation. Use Caution/Monitor.

                  • perphenazine

                    dexchlorpheniramine and perphenazine both increase sedation. Use Caution/Monitor.

                  • phendimetrazine

                    dexchlorpheniramine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • phenelzine

                    phenelzine increases effects of dexchlorpheniramine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .

                  • phenobarbital

                    dexchlorpheniramine and phenobarbital both increase sedation. Use Caution/Monitor.

                  • phentermine

                    dexchlorpheniramine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • phenylephrine

                    dexchlorpheniramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • phenylephrine PO

                    dexchlorpheniramine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

                  • pholcodine

                    dexchlorpheniramine and pholcodine both increase sedation. Use Caution/Monitor.

                  • pimozide

                    dexchlorpheniramine and pimozide both increase sedation. Use Caution/Monitor.

                  • pirbuterol

                    dexchlorpheniramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • pregabalin

                    pregabalin, dexchlorpheniramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

                  • primidone

                    dexchlorpheniramine and primidone both increase sedation. Use Caution/Monitor.

                  • prochlorperazine

                    dexchlorpheniramine and prochlorperazine both increase sedation. Use Caution/Monitor.

                  • promethazine

                    dexchlorpheniramine and promethazine both increase sedation. Use Caution/Monitor.

                  • propofol

                    propofol and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • propylhexedrine

                    dexchlorpheniramine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • protriptyline

                    dexchlorpheniramine and protriptyline both increase sedation. Use Caution/Monitor.

                  • quazepam

                    dexchlorpheniramine and quazepam both increase sedation. Use Caution/Monitor.

                  • quetiapine

                    dexchlorpheniramine and quetiapine both increase sedation. Use Caution/Monitor.

                  • ramelteon

                    dexchlorpheniramine and ramelteon both increase sedation. Use Caution/Monitor.

                  • risperidone

                    dexchlorpheniramine and risperidone both increase sedation. Use Caution/Monitor.

                  • salmeterol

                    dexchlorpheniramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • scullcap

                    dexchlorpheniramine and scullcap both increase sedation. Use Caution/Monitor.

                  • secobarbital

                    dexchlorpheniramine and secobarbital both increase sedation. Use Caution/Monitor.

                  • sevoflurane

                    sevoflurane and dexchlorpheniramine both increase sedation. Use Caution/Monitor.

                  • shepherd's purse

                    dexchlorpheniramine and shepherd's purse both increase sedation. Use Caution/Monitor.

                  • stiripentol

                    stiripentol, dexchlorpheniramine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

                  • sufentanil

                    dexchlorpheniramine and sufentanil both increase sedation. Use Caution/Monitor.

                  • tapentadol

                    dexchlorpheniramine and tapentadol both increase sedation. Use Caution/Monitor.

                  • temazepam

                    dexchlorpheniramine and temazepam both increase sedation. Use Caution/Monitor.

                  • terbutaline

                    dexchlorpheniramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • thioridazine

                    dexchlorpheniramine and thioridazine both increase sedation. Use Caution/Monitor.

                  • thiothixene

                    dexchlorpheniramine and thiothixene both increase sedation. Use Caution/Monitor.

                  • topiramate

                    dexchlorpheniramine and topiramate both increase sedation. Modify Therapy/Monitor Closely.

                  • tramadol

                    dexchlorpheniramine and tramadol both increase sedation. Use Caution/Monitor.

                  • trazodone

                    dexchlorpheniramine and trazodone both increase sedation. Use Caution/Monitor.

                  • triazolam

                    dexchlorpheniramine and triazolam both increase sedation. Use Caution/Monitor.

                  • triclofos

                    dexchlorpheniramine and triclofos both increase sedation. Use Caution/Monitor.

                  • trifluoperazine

                    dexchlorpheniramine and trifluoperazine both increase sedation. Use Caution/Monitor.

                  • trimipramine

                    dexchlorpheniramine and trimipramine both increase sedation. Use Caution/Monitor.

                  • triprolidine

                    dexchlorpheniramine and triprolidine both increase sedation. Use Caution/Monitor.

                  • valerian

                    valerian increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

                  • xylometazoline

                    dexchlorpheniramine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • yohimbine

                    dexchlorpheniramine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • ziconotide

                    dexchlorpheniramine and ziconotide both increase sedation. Use Caution/Monitor.

                  • ziprasidone

                    dexchlorpheniramine and ziprasidone both increase sedation. Use Caution/Monitor.

                  • zotepine

                    dexchlorpheniramine and zotepine both increase sedation. Use Caution/Monitor.

                  Minor (6)

                  • ashwagandha

                    ashwagandha increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

                  • brimonidine

                    brimonidine increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

                  • eucalyptus

                    dexchlorpheniramine and eucalyptus both increase sedation. Minor/Significance Unknown.

                  • nettle

                    nettle increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression.

                  • sage

                    dexchlorpheniramine and sage both increase sedation. Minor/Significance Unknown.

                  • Siberian ginseng

                    Siberian ginseng increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: B

                  Lactation: excretion in milk unknown/not recommended

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  Histamine H1-receptor antagonist in blood vessels, respiratory tract, and gastrointestinal tract

                  Pharmacokinetics

                  Half-Life: 20-30 hr

                  Onset: 6 hr

                  Duration: 24 hr

                  Peak Plasma Time: 3 hr

                  Protein Bound: 69-72%

                  Excretion: Urine

                  Vd: 2.5-3.2 L/kg (adults); 3.8 L/kg (Children)

                  Metabolism: Hepatic

                  Metabolites: Unidentified, at least 2

                  Sedative effects: Low

                  Antihistamine activity: High

                  Anticholinergic activity: Moderate

                  Previous
                  Next:

                  Images

                  No images available for this drug.
                  Previous
                  Next:

                  Patient Handout

                  A Patient Handout is not currently available for this monograph.
                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Create Your List of Plans

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  View explanations for tiers and restrictions
                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  CLOSE
                  Additional Offers
                  CLOSE
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  CLOSE
                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
                  Find Us On
                  About
                  About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
                  Membership
                  Become a Member About You Professional Information Newsletters & Alerts Market Research
                  App
                  Medscape
                  WebMD Network
                  Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
                  Editions
                  English Deutsch Español Français Português UK
                  All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.